en · de · es · pt
epitalon-notes.peptides3081.com › Data › Research Claims And Evidence Status — Research Overview

Research Claims And Evidence Status — Research Overview

By Editorial Desk · published 2025-08-26 · last reviewed 2025-10-05 · Data

A practical reference on research chemical: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

This page was last updated on 2025-10-05 and is reviewed periodically as new material appears.

Research Claims and Evidence Status

The most frequently cited laboratory finding is that AEDG increased telomerase activity and extended telomere length in cultured human somatic cells. That work used fetal fibroblast strains and reported changes in enzyme activity alongside altered division counts. Replication by unrelated groups has been limited, and the published record is largely a single-laboratory series rather than a multi-centre programme. The result supports a hypothesis about peptide influence on gene expression in cell culture; it does not by itself establish an effect on telomere length in living animals or in people.

Animal and clinical reports appear mainly in Russian-language journals from the 1990s and 2000s, covering endpoints such as melatonin rhythm, lifespan in aged rodents, and retinal function. Many of these papers involve small groups, lack blinding or placebo comparison, and are difficult to retrieve through indexed databases. Review articles published in English generally summarise the claims without reanalysing the underlying data. Because no large randomised trial exists, the clinical importance of these reported effects stays unresolved and is properly described as an open question.

Background and Proposed Mechanism

Epitalon is a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, commonly abbreviated AEDG. It was designed at the St. Petersburg Institute of Bioregulation and Gerontology as a short, chemically defined analogue of epithalamin, a fraction obtained from bovine pineal tissue. Small peptide bioregulators of this type formed a long-running line of work there from the 1980s onward. Because the molecule is produced by solid-phase synthesis rather than extraction, its composition is exact and its purity can be measured directly.

The most frequently cited proposed action is induction of telomerase, the enzyme that adds repeat sequences to chromosome ends. Cell-culture work from the originating group reported higher telomerase reverse transcriptase expression and measurable telomere elongation in human somatic cells after exposure. How a four-residue peptide would reach nuclear gene regulation is not established, and no cell-surface receptor or uptake route has been identified. Additional reports describe changes in melatonin secretion, antioxidant enzyme activity and lipid peroxidation in aged animals, but these findings remain mechanistically unconnected to the telomerase observation.

Published evidence comes mainly from Russian-language journals and from a single research group, with small sample sizes and limited independent replication. A few laboratories outside that group have examined related peptides and reported weaker or absent telomerase effects, so the central claim is best described as contested rather than settled. Rodent studies report modest changes in some ageing markers and in survival, but designs vary and control conditions are often sparse. No large randomised trial in humans has been published, and long-term safety data in healthy populations are correspondingly thin.

Epitalon at a glance

PropertyValueNotes
Regulatory statusNot an approved drugMarketed in most countries as a research chemical
Main literature languageRussian and EnglishEarly reports concentrated in Russian journals
Typical stated purity≥95% by HPLCSupplier declaration, seldom independently verified
Principal studied endpointTelomerase activity in vitroMeasured in cultured human cells
Reported administration routesSubcutaneous, intranasalDescribed in exploratory use reports

Storage, Assay, and Regulatory Framework

Identity and purity are checked by reversed-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, where the peptide bond absorbs. Mass spectrometry confirms the expected mass and reveals whether truncation products or adducts are present. Acid hydrolysis followed by amino acid analysis gives the residue ratio, which should approximate one alanine, one glutamate, one aspartate and one glycine. Counter-ions such as acetate or trifluoroacetate remain in the dried product and lower net peptide content, so a stated purity figure on a label does not by itself describe how much peptide a vial holds.

Regulatory treatment differs by country. No formulation of epitalon holds a marketing authorisation as a medicine in the United States or the European Union, where material sold for laboratory use is handled as a research chemical and is not intended for human consumption. In Russia, several short peptide preparations from the same institute's peptide series are registered medicinal products, and epitalon appears in that national context. Elsewhere it is frequently offered as a cosmetic ingredient, a category with lighter requirements. Advertising claims about longevity or disease prevention are restricted in most jurisdictions, which limits how sellers describe the compound.

Related pages on this site

Peptide Identity and Laboratory Handling

Epitalon is a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, abbreviated AEDG. Its molecular formula is C14H22N4O9 and its calculated monoisotopic mass is approximately 390.35 daltons. The compound does not occur naturally as a free peptide; it is produced by solid-phase peptide synthesis. Because it contains two acidic residues and no basic residues, the neutral form carries a net negative charge at physiological pH. This charge profile influences how the peptide behaves in solution and during chromatographic analysis.

Laboratory-grade epitalon is typically supplied as a lyophilized powder. Purity is commonly assessed with reverse-phase high-performance liquid chromatography, often paired with mass spectrometry to confirm molecular identity. Amino acid analysis and peptide mapping can provide additional confirmation of sequence. Certificates of analysis for research materials frequently report purity above 95 percent, although the methods behind such figures vary between suppliers. The absence of a pharmacopeial monograph means that no single standardized assay defines the compound, so reported results depend on the analytical protocol chosen.

Storage recommendations center on limiting moisture, heat, and light. The dry powder is generally kept at minus 20 degrees Celsius, and some suppliers recommend minus 80 degrees for long-term archival. Once dissolved, solutions are usually aliquoted and frozen to avoid repeated freeze-thaw cycles, which can promote aggregation or degradation. Aqueous stability depends on pH and concentration, and buffered saline is often preferred over plain water for biological work. Stability data specific to epitalon remain limited, so general peptide-handling practices are applied by analogy rather than from product-specific validation.

Origin and Telomerase Research Claims

The most widely cited claim is that epitalon activates telomerase and thereby extends telomere length. Supporting evidence comes largely from cultured human cells, where treatment was associated with increased telomerase activity and delayed replicative senescence. Telomerase activation is a biologically consequential effect, since the enzyme is largely silenced in most somatic cells. However, the route by which a short peptide would reach and act on the enzyme's regulatory machinery has not been established. Independent replication in human trials is scarce, so the link between cell-culture observations and whole-body aging remains an open question.

Human data are limited to small studies, often without the randomization, blinding, or control groups expected in contemporary clinical research. Reported outcomes have included changes in melatonin levels, immune markers, and subjective measures, but sample sizes were generally too small to support firm conclusions. Some reviews treat the peptide as promising while noting methodological weaknesses; others question whether the observed effects are specific. The compound is frequently discussed in longevity-focused communities, where enthusiasm often outpaces the published evidence. Separating established findings from speculation is therefore important when reading summaries of this research.

Epitalon emerged from research conducted in Saint Petersburg by Vladimir Khavinson and colleagues, who studied short peptides as potential regulators of aging. The work built on epithalamin, a pineal gland extract reported to influence neuroendocrine function. Epitalon was designed as a synthetic counterpart with a defined sequence, allowing reproducible experiments that extracts could not support. Early publications described effects on melatonin rhythms and lifespan in animal models. These findings circulated mainly in Russian-language journals during the 1990s, which limited their visibility among English-speaking researchers.

Identity and Research Background

Published work on this compound consists mainly of in vitro experiments, animal studies, and small clinical investigations, a substantial share of which appeared in Russian-language journals. Sample sizes are generally small, control conditions differ between studies, and several endpoints rely on markers whose clinical meaning is itself debated. Reviews of the longevity field treat the peptide as an early example of telomerase-directed research rather than an established intervention. Regulatory treatment varies by country: some jurisdictions place it under prescription controls, others treat it as a laboratory material, and importation may be restricted regardless of local status.

Epitalon is a synthetic tetrapeptide whose sequence is alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. It was developed in Russia during the 1980s and 1990s by investigators associated with the St. Petersburg Institute of Bioregulation and Gerontology, who studied short peptides as regulators of gene expression and tissue function. The alternative spelling epithalon appears interchangeably in the literature, and the two names refer to the same molecule. Outside Russia it is encountered chiefly as a research chemical rather than a licensed medicine, and it holds no approval from the United States Food and Drug Administration or the European Medicines Agency.

The peptide is a synthetic analogue of epithalamin, a preparation extracted from bovine pineal glands. Investigators sought a short, chemically defined molecule that would reproduce some of the endocrine and gerontological observations attributed to the glandular extract. Proposed mechanisms centre on induction of telomerase activity, an effect reported in cultured human somatic cells in the early 2000s, together with influences on melatonin secretion and neuroendocrine regulation. Those mechanisms remain incompletely characterised, and the reported telomerase response has not been consistently reproduced by independent groups working in comparable systems.

Notes from published material

In November 2021, CleanTechnica reported that Tesla would be opening Superchargers at 26 Buc-ee's locations in seven states. As of February 2023, there were operational Superchargers at more than half of the planned locations including in Alabama (Leeds and Robertsdale); Florida (St. Augustine); South Carolina (Florence); Tennessee (Crossville); and Texas (Bastrop, Baytown, Ennis, Giddings, Katy, Madisonville, Melissa, New Braunfels, and Wharton). Since then, more Superchargers have been added into more locations, such as in Colorado (Berthoud); Florida (Daytona Beach); Georgia (Adalrsville and Fort Valley); Kentucky (Richmond); Tennessee (Kodak); and Texas (Denton, Fort Worth, Luling, Pearland, Royse City, Temple, Terrell, and Waller).

=== Relationship to Donald Trump === A key reason for Hillbilly Elegy's widespread popularity following its publication in 2016 was its role in explaining Donald Trump's rise to the top of the Republican Party. In particular, it purportedly explains why white, working-class voters became attracted to Trump as a political leader. Vance himself offered commentary on how his book provides perspective on why a voter from the "hillbilly" demographic would support Trump. Although he does not mention Trump in the book, Vance openly criticized the then presidential candidate while discussing his memoir in a 2016 interview following the book's release. Vance walked these comments back when he joined the 2022 U.S. Senate race in Ohio, and later openly endorsed Trump. In July 2024, Vance was picked by Trump to be his running mate on the Republican ticket for the 2024 U.S. presidential election.

ISBN 978-0-87220-923-7. Powell, Anton (1990). Euripides, Women and Sexuality. Routledge Press. ISBN 0-415-01025-X. Pucci, Pietro. "Survival in the Holy Garden." The Violence of Pity In Euripides’ “Medea,” vol. 41, Cornell University Press, 1980, pp. 91–130. JSTOR, http://www.jstor.org/stable/10.7591/j.cttq44w0.6. Accessed 27 Mar. 2023. Rabinowitz, Nancy S. (1993). Anxiety Veiled: Euripides and the Traffic in Women. Cornell University Press. ISBN 0-8014-8091-4. Saïd, Suzanne (2002). "Greeks and Barbarians in Euripides' Tragedies: The End of Differences?". In Harrison, Thomas (ed.). Greeks and Barbarians. Translated by Antonia Nevill. Taylor & Francis. ISBN 0-415-93959-3. Sommerstein, Alan (2002). Greek Drama and Dramatists. Routledge Press. ISBN 0-203-42498-0. ISBN 978-0-203-42498-8 Tessitore, Aristide. "Euripides’ ‘Medea’ and the Problem of Spiritedness." The Review of Politics, vol. 53, no. 4, 1991, pp. 587–601. JSTOR, JSTOR 1407307. Accessed 27 Apr. 2023. Tigani, Francesco (2010), Rappresentare Medea. Dal mito al nichilismo, Aracne. ISBN 978-88-548-3256-5 Mossman, Judith (2011). Medea: Introduction, Translation and Commentary. Warminster: Aris & Phillips. ISBN 978-0-856-68788-4.

Sources: en.wikipedia.org

Further detail

=== Adolfo Suárez's second government (1977–1979) === The measure that the newly elected deputies of the Cortes considered most urgent was to enact a total amnesty law that would free the prisoners who were still in jail for "politically motivated" crimes, including those "of blood". The left accepted that the law also covered people who had committed crimes during Franco's repression, which constituted a kind of "pact of oblivion" because, as the communist Marcelino Camacho, imprisoned during the dictatorship, said, "how could we reconcile those of us who had been killing each other, if we did not erase that past once and for all?". However, despite the fact that the Amnesty Law released all the "Basque prisoners", ETA not only did not abandon "armed combat" but also increased the number of attacks ─ in 1978, it perpetrated 71 resulting in 85 deaths.

== Causes == Hair insertion is the causative agent of pilonidal cysts. An analysis of 624 patients' cyst hair found that 74% of the hair was rootless, and resembled spiky, razor-cut hair rather than intact body hair. One proposed cause is ingrown hair, although hairs found in pilonidal sinus tracts have more often been found to originate from the head. Excessive sitting is thought to predispose people to the condition, as sitting increases pressure on the coccygeal region. Trauma is not believed to cause a pilonidal cyst; however, such an event may result in inflammation of an existing cyst. There are cases where this has occurred months after a localized injury to the area. Pilonidal cysts may be caused by a congenital pilonidal dimple. Excessive sweating can also contribute to the formation of a pilonidal cyst: moisture can fill a stretched hair follicle, which helps create a low-oxygen environment that promotes the growth of anaerobic bacteria, often found in pilonidal cysts. The presence of bacteria and low oxygen levels hamper wound healing and exacerbate a developing pilonidal cyst.

This standard was written for a biological manufacturing company and was then written into the PDA's Technical Report # 39, thus establishing the industry standard for cold chain validation. This was critical for the industry due to the sensitivity of drug substances, biologics and vaccines to various temperature conditions. The FDA has also been very focused on this final area of distribution and the potential for a drug substances quality to be impacted by extreme temperature exposure. 4.6. Accuracy: Accuracy of an analytical procedure is the closeness of test results obtained by that procedure to the true value. The accuracy of an analytical procedure shall be established across its range. 4.7. Precision: The precision of an analytical procedure expresses the closeness of agreement between a series of measurements obtained from multiple sampling of the same homogeneous sample under the prescribed conditions. 4.8. Method precision (Repeatability): Method precision carried out on different test preparation of a homogenous sample within short interval of time under same experimental conditions. 4.9. Intermediate precision (Ruggedness): Intermediate precision (Ruggedness) expresses within-laboratories variations i.e. different days, different analysts, different equipment etc. 4.10. Range: The range of an analytical procedure is the interval between the upper and lower concentration of analyte in the sample for which it has been demonstrated that the analytical procedure has a suitable level of precision, accuracy and linearity

=== Scams === In the early 2000s, numerous companies advertised açaí products online, with many ads featuring counterfeit testimonials and products. In 2009, açaí scams were ranked No. 1 on the U.S. Federal Trade Commission's "scams and rip-offs" list, so that by 2011 sales of açaí flattened as the fad waned. According to the Washington, D.C.–based Center for Science in the Public Interest thousands of consumers had trouble stopping recurrent charges on their credit cards when they canceled free trials of some açai-based products. In 2003, American celebrity doctor Nicholas Perricone included açaí berries among "superfoods", but such extravagant marketing claims regarding açaí as miracle cures for everything from obesity to attention-deficit disorder were challenged in subsequent studies. The FTC handed down an $80 million judgement in January 2012 against five companies that were marketing açaí berry supplements with fraudulent claims that their products promoted weight loss and prevented colon cancer. One company, Central Coast Nutraceuticals, was ordered to pay a $1.5 million settlement.

Sources: en.wikipedia.org

Supporting material

upstream activating sequence (UAS) Also upstream activator sequence and upstream activation sequence. A type of cis-acting regulatory element found in the DNA of yeast such as Saccharomyces cerevisiae, usually a few hundred base pairs upstream of the transcription initiation site within the promoter of a protein-coding gene, which helps to increase the gene's expression by serving as a binding site for transcriptional transactivators, analogous to the function of an enhancer in multicellular eukaryotes.

== References == ADA - CSII Diabetes Care 2004; 27: S110. ADA - Implications of the DCCT study Diabetes Care 2002; 25: 25–27. ADA - Implications of the UKPD Study Diabetes Care 2002; 25: 28–32. Bell D.S.H., Fernando O. (2000). "Improved glycemic control with use of CSII compared with MDI therapy". Endocrine Practice. 6 (5): 257–360. doi:10.4158/EP.6.5.357. PMID 11141585. Binder C., Lauritzen T., Faber O., Pramming S. (1984). "Insulin pharmacokinetics". Diabetes Care. 7 (2): 188–99. doi:10.2337/diacare.7.2.188. PMID 6376015. S2CID 29287604.{{cite journal}}: CS1 maint: multiple names: authors list (link) Bode B.W., Steed R.D., Davidson P.C. (1996). "Reduction in severe hypoglycemia with longterm CSII in type 1 diabetes". Diabetes Care. 19 (4): 324–7. doi:10.2337/diacare.19.4.324. PMID 8729154. S2CID 29779558.{{cite journal}}: CS1 maint: multiple names: authors list (link) Bode BW; et al. (1999). "Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: A pilot study". Diabetes Research and Clin Practice. 46 (3): 183–90. doi:10.1016/S0168-8227(99)00113-8. PMID 10624783. Diabetes Technol Ther. 2004;6(2):105-13. Boland E.A., Grey M.; et al. (1999). "CSII - a new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes". Diabetes Care. 22 (11): 1779–84. doi:10.2337/diacare.22.11.1779. PMID 10546007. Carlton F.B. (2000). "Recent advances in the pharmacologic management of diabetes mellitus". Emergency Medicine Clinics of North America. 18 (4): 745–53.

Nonetheless, Moniz's reported successful surgical treatment of 14 out of 20 patients led to the rapid adoption of the procedure on an experimental basis by individual clinicians in countries such as Brazil, Cuba, Italy, Romania and the United States during the 1930s.

Sources: en.wikipedia.org

Frequently asked questions

Has epitalon been studied in people?

Small studies with human participants have been reported, chiefly in Russian-language journals, but they are limited in size and design. No large randomised controlled trial with published results is available.

What is the strongest evidence for its activity?

The most reproducible biochemical observation comes from cultured cells, where the peptide was reported to raise telomerase activity. Whether this translates into measurable health effects in animals or humans is not established.

Why is epitalon sold online?

It is offered as a research chemical for laboratory use, which places it outside the approval pathways applied to medicines. Buyers should expect documentation to differ between suppliers.

Is epitalon the same substance as epithalamin?

No. Epithalamin is a peptide-containing extract of bovine pineal glands, while epitalon is a single synthetic tetrapeptide. The extract contains many peptides and other tissue components, so its composition varies between batches in ways that a synthesised sequence does not.

Network